Gilead Sciences, Inc.
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 13, 2025), Gilead Sciences, Inc. reported 16 stock positions worth $1.6 billion. Its top holding was Arcellx (ACLX) at 33.2% of the portfolio, followed by Lakefront Biotherapeutic-ADR (LKFT, 29.8%) and Arcus Biosciences (RCUS, 28.9%).
- Most Recent 13F
- Q2 2026
- Location
- FOSTER CITY, CA
- CIK
- 0000882095
- Portfolio Value
- $1.6B (Q4 2024)
- SEC Filing
- 0001123292-25-000079 ↗ filed Feb 13, 2025
Holdings Value
Holdings 16 stocks · $1.6B
| ACLX Arcellx Inc. | 33.23% | 6,720,803 | $515.4M | — |
| LKFT Lakefront Biotherapeutic-ADR filed as GALAPAGOS NV | 29.77% | 16,707,477 | $461.7M | — |
| RCUS Arcus Biosciences Inc. | 28.86% | 30,061,124 | $447.6M | — |
| ASMB Assembly Biosciences Inc. | 2.25% | 2,209,471 | $34.9M | — |
| MRUS Merus NV | 1.23% | 452,527 | $19.0M | — |
| KYTX Kyverna Therapeutics Inc. | 0.99% | 4,126,119 | $15.4M | — |
| CYPH Cypherpunk Technologies Inc. filed as LEAP THERAPEUTICS INC | 0.99% | 5,319,148 | $15.3M | — |
| TNGX Tango Therapeutics Inc. | 0.97% | 4,854,443 | $15.0M | — |
| XLO Xilio Therapeutics Inc. | 0.56% | 9,105,451 | $8.7M | — |
| ALLOVIR INC | 0.45% | 16,635,286 | $7.0M | — |
| HOOK Hookipa Pharma Inc. | 0.24% | 1,875,945 | $3.8M | — |
| IKENA ONCOLOGY INC | 0.21% | 2,008,338 | $3.3M | — |
| ALLO Allogene Therapeutics Inc. | 0.16% | 1,156,689 | $2.5M | — |
| BRNS Barinthus Biotherapeutics PL | 0.05% | 620,351 | $749K | — |
| AGEN Agenus Inc. | 0.04% | 231,663 | $635K | — |
| KRON Kronos Bio Inc. | 0.01% | 188,567 | $179K | — |
Portfolio Sells Q4 2024
No earlier filing to compare with.
Portfolio Buys Q4 2024
No earlier filing to compare with.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 5 | $1.6B | RCUS, LKFT, ASMB, KYTX, XLO |
| Q1 2026 | 6 | $2.1B | ACLX, RCUS, LKFT, ASMB, KYTX |
| Q4 2025 | 6 | $1.9B | RCUS, LKFT, ACLX, ASMB, KYTX |
| Q3 2025 | 9 | $1.8B | LKFT, ACLX, RCUS, ASMB, MRUS |
| Q2 2025 | 14 | $1.3B | LKFT, ACLX, RCUS, ASMB, TNGX |
| Q1 2025 | 14 | $1.2B | ACLX, LKFT, RCUS, ASMB, MRUS |
| Q4 2024 | 16 | $1.6B | ACLX, LKFT, RCUS, ASMB, MRUS |